VOLITIONRX LTD (VNRX)

↓ Download CSV

CIK 0000093314 · NYSE · In Vitro & In Vivo Diagnostic Substances

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, VOLITIONRX LTD reported revenue of $1.73M, up 40.0% from the prior year. The company ran a net loss, with a net margin of -1352.2%. It held $6.90M in total assets against $42.49M in total liabilities.

Key ratios (FY2025)

-1258.5%
Operating margin
-1352.2%
Net margin
+40.0%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$1.73M$1.23M$775.3K$306.4K$90.0K$13.4K$17.1K
Operating Income-$21.74M-$27.02M-$35.99M-$31.78M-$28.33M-$21.25M-$16.04M-$17.90M-$14.70M-$12.43M
Net Income-$23.36M-$26.97M-$35.68M-$30.60M-$26.99M-$20.40M-$16.10M-$18.01M-$11.91M
EPS (Diluted)$-0.31$-0.50
Total Assets$6.90M$9.40M$27.95M$18.30M$27.49M$26.15M$21.29M$17.49M$14.62M$24.73M
Total Liabilities$42.49M$35.51M$36.66M$21.42M$9.77M$9.86M$7.09M$5.35M$4.67M$3.56M
Shareholders' Equity-$34.25M-$24.91M-$7.80M-$2.57M$17.72M$16.29M$14.20M$12.14M$9.96M$21.18M
Cash & Equivalents$1.12M$3.26M$20.73M$10.87M$20.58M$19.44M$16.97M$13.43M$10.12M$21.68M
Operating Cash Flow-$19.68M-$25.89M-$18.06M-$15.28M-$20.85M-$16.46M-$12.74M-$14.73M-$12.19M-$8.86M
Capital Expenditures$89.6K$277.5K$1.08M$1.57M$973.6K$1.94M$511.3K-$301.8K$1.43M$415.1K
Shares Outstanding125.78M96.10M81.90M57.87M53.77M48.61M41.13M35.34M26.52M26.13M